TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 32935997

Group type: EXPERIMENTAL
Intervention: Molecular-targeted treatments
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control arm patients
Number of subjects: 0
Study: 32966982

Group type: EXPERIMENTAL
Intervention: Onabotulinum toxin A (BoNT‐A)
Number of subjects: 30
Study: 33892048

Group type: EXPERIMENTAL
Intervention: Hyperosmolar eye drops
Number of subjects: 68

Group type: COMPARATOR
Intervention: Artificial tears (placebo)
Number of subjects: 68
Study: 35946123

Group type: EXPERIMENTAL
Intervention: 0.05% Cetylpyridinium Chloride (CPC) mouthwash
Number of subjects: 219

Group type: EXPERIMENTAL
Intervention: 0.12% Chlorhexidine Gluconate (CHX) mouthwash
Number of subjects: 219

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 219
Study: 34689304

Group type: EXPERIMENTAL
Intervention: New galenics nasal spray (nasic® neo)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Comparator nasal spray
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: New galenics nasal spray (nasic® neo) in subgroup with pronounced inflammation
Number of subjects: 0
Study: 32907366

Group type: EXPERIMENTAL
Intervention: BMS-986141 (400 ng/mL)
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: BMS-968141 (combined with low-dose apixaban)
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: Apixaban (low-dose 20 ng/mL)
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: BMS-986141 (combined with apixaban)
Number of subjects: 15
Study: 36415003

Group type: EXPERIMENTAL
Intervention: Dual task (DT) training for three weekly sessions for 8 weeks, 60 min each
Number of subjects: 30

Group type: COMPARATOR
Intervention: Activities of daily living
Number of subjects: 30
Study: 32751196

Group type: EXPERIMENTAL
Intervention: Maternal 25(OH)D plasma levels
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Breast milk levels of 25(OH)D
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Infant plasma levels
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Correlation between mother and infant plasma levels
Number of subjects: 0
Study: 36183051

Group type: EXPERIMENTAL
Intervention: Socio-Cognitive Behavioral Therapy for Suicidal Behaviors (SCBT-SB)
Number of subjects: 46

Group type: COMPARATOR
Intervention: Treatment-as-usual (TAU)
Number of subjects: 46
Study: 33269798

Group type: EXPERIMENTAL
Intervention: Sinovac EV71 vaccine (Older-S group)
Number of subjects: 600

Group type: COMPARATOR
Intervention: Control EV71 vaccine (Older-C group)
Number of subjects: 600

Group type: EXPERIMENTAL
Intervention: Sinovac EV71 vaccine (Younger-S group)
Number of subjects: 600
Study: 32381420

Group type: EXPERIMENTAL
Intervention: Atezolizumab plus pemetrexed/carboplatin
Number of subjects: 0

Group type: COMPARATOR
Intervention: Atezolizumab, pemetrexed/carboplatin, and bevacizumab
Number of subjects: 0
Study: 33129962

Group type: EXPERIMENTAL
Intervention: Midline catheter-based IV strategy
Number of subjects: 120
Study: 32449542

Group type: EXPERIMENTAL
Intervention: Subthalamic deep brain stimulation (STN-DBS)
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: Stimulation off/medication on condition
Number of subjects: 36

Group type: COMPARATOR
Intervention: Stimulation off
Number of subjects: 36
Study: 33360684

Group type: EXPERIMENTAL
Intervention: Lys-FFA (500 mg EPA plus 302 mg DHA)
Number of subjects: 8

Group type: COMPARATOR
Intervention: EE (504 mg EPA plus 378 mg DHA)
Number of subjects: 8
Study: 34807806

Group type: EXPERIMENTAL
Intervention: Instructor-directed feedback
Number of subjects: 40

Group type: COMPARATOR
Intervention: Self-assessment using video
Number of subjects: 40
Study: 35940567

Group type: EXPERIMENTAL
Intervention: TDF/FTC plus HCQ
Number of subjects: 926

Group type: EXPERIMENTAL
Intervention: TDF/FTC placebo plus HCQ
Number of subjects: 926

Group type: EXPERIMENTAL
Intervention: HCQ plus TDF/FTC placebo
Number of subjects: 926

Group type: COMPARATOR
Intervention: TDF/FTC placebo plus HCQ placebo
Number of subjects: 926
Study: 34469796

Group type: EXPERIMENTAL
Intervention: Hematoporphyrin derivative
Number of subjects: 25

Group type: EXPERIMENTAL
Intervention: 0.12% Chlorhexidine digluconate
Number of subjects: 25

Group type: COMPARATOR
Intervention: Sodium perborate enzyme
Number of subjects: 25

Group type: COMPARATOR
Intervention: Citric acid
Number of subjects: 25
Study: 33905630

Group type: EXPERIMENTAL
Intervention: OneTouch Reveal app (used for 12 weeks) in Subgroup C (fixed insulin dose)
Number of subjects: 75

Group type: EXPERIMENTAL
Intervention: OneTouch Reveal app (used for 12 weeks) in Subgroup B (carbohydrate counting)
Number of subjects: 75

Group type: COMPARATOR
Intervention: Control group (Group A, treated with continuous subcutaneous insulin infusion (CSII))
Number of subjects: 75
Study: 33386821

Group type: EXPERIMENTAL
Intervention: Whole body cryotherapy (WBC), 20 sessions
Number of subjects: 114

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 114
Study: 33078435

Group type: EXPERIMENTAL
Intervention: Daily aerobic cycling exercise (35 min at 60% VO2max)
Number of subjects: 31

Group type: COMPARATOR
Intervention: Control group (stretching routine)
Number of subjects: 31

Group type: COMPARATOR
Intervention: Both groups
Number of subjects: 31
Study: 32503602

Group type: EXPERIMENTAL
Intervention: BCG vaccine (0.1 ml of the licensed BCG vaccine, Danish strain 1331, SSI, Denmark, equivalent to 0.075 mg attenuated M. bovis)
Number of subjects: 3100

Group type: COMPARATOR
Intervention: Placebo (0.1 ml 0.9% NaCl)
Number of subjects: 3100
Study: 33588784

Group type: EXPERIMENTAL
Intervention: Foreign language learning (Spanish course for beginners)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Waiting list control group
Number of subjects: 60
Study: 35349884

Group type: EXPERIMENTAL
Intervention: Aerobic exercise combined with Frenkel Coordination Exercises, 3 sessions per week for 6 weeks
Number of subjects: 32

Group type: COMPARATOR
Intervention: Frenkel Coordination Exercise training (Control Group)
Number of subjects: 32
Study: 33752964

Group type: EXPERIMENTAL
Intervention: Participants with at least one ED visit
Number of subjects: 101

Group type: EXPERIMENTAL
Intervention: Participants with incident ED visits
Number of subjects: 101
Study: 36084065

Group type: EXPERIMENTAL
Intervention: Conventional IVES
Number of subjects: 76

Group type: COMPARATOR
Intervention: IVES with an open circuit
Number of subjects: 76
Study: 35372857

Group type: EXPERIMENTAL
Intervention: HDF
Number of subjects: 24

Group type: COMPARATOR
Intervention: HD
Number of subjects: 24
Study: 35038432

Group type: EXPERIMENTAL
Intervention: Sugemalimab plus platinum-based chemotherapy (1200 mg intravenously every 3 weeks)
Number of subjects: 479

Group type: COMPARATOR
Intervention: Placebo plus platinum-based chemotherapy
Number of subjects: 479

Group type: EXPERIMENTAL
Intervention: Sugemalimab plus chemotherapy
Number of subjects: 479

Group type: COMPARATOR
Intervention: Placebo plus chemotherapy
Number of subjects: 479

Group type: EXPERIMENTAL
Intervention: Sugemalimab
Number of subjects: 479

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 479
Study: 33373011

Group type: EXPERIMENTAL
Intervention: 3D-endoscopic technique
Number of subjects: 80

Group type: COMPARATOR
Intervention: 2D-endoscopic technique
Number of subjects: 80

Group type: COMPARATOR
Intervention: Comparison of 2D vs 3D
Number of subjects: 80
Study: 36498288

Group type: EXPERIMENTAL
Intervention: Therapy using PNF, NDT-Bobath methods and the SPIDER system
Number of subjects: 120

Group type: COMPARATOR
Intervention: Therapy using PNF and NDT-Bobath methods, without the SPIDER system
Number of subjects: 120
Study: 32458554

Group type: EXPERIMENTAL
Intervention: Cognitive behavioural therapy (CBT)
Number of subjects: 58

Group type: COMPARATOR
Intervention: Control condition
Number of subjects: 58
Study: 32827269

Group type: EXPERIMENTAL
Intervention: Dapagliflozin 10 mg
Number of subjects: 20

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study: 35679057

Group type: EXPERIMENTAL
Intervention: Virtual Reality (VR) using Oculus Quest headset
Number of subjects: 29

Group type: COMPARATOR
Intervention: Control using handheld smartphone device
Number of subjects: 29
Study: 32734504

Group type: EXPERIMENTAL
Intervention: 12-months web-based intensive prevention program
Number of subjects: 0

Group type: COMPARATOR
Intervention: Standard care
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Web-based intensive prevention program with genetic risk disclosure
Number of subjects: 0

Group type: COMPARATOR
Intervention: Web-based intensive prevention program without genetic risk disclosure
Number of subjects: 0
Study: 34456847

Group type: EXPERIMENTAL
Intervention: Tonbridge stent
Number of subjects: 220

Group type: COMPARATOR
Intervention: Solitaire FR
Number of subjects: 220
Study: 35914257

Group type: EXPERIMENTAL
Intervention: Smartphone application for self-managing a FODMAP-lowering diet
Number of subjects: 0

Group type: COMPARATOR
Intervention: Otilonium bromide
Number of subjects: 0
Study: 33427305

Group type: EXPERIMENTAL
Intervention: NSAID
Number of subjects: 5136
Study: 33378508

Group type: EXPERIMENTAL
Intervention: Double-extraction group (DEG)
Number of subjects: 32

Group type: COMPARATOR
Intervention: Single-extraction group (SEG)
Number of subjects: 32
Study: 36287379

Group type: EXPERIMENTAL
Intervention: RBX2660
Number of subjects: 289

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 289
Study: 33928755

Group type: EXPERIMENTAL
Intervention: Multiple mobile health devices (Fitbit Alta® fitness tracker, iHealth® glucometer, BodyTrace® scale)
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Visualizations generated from health data obtained from the three devices
Number of subjects: 20
Study: 36149770

Group type: EXPERIMENTAL
Intervention: Vitamin C (VITC; ∼2‐3 g)
Number of subjects: 27

Group type: EXPERIMENTAL
Intervention: Oral BH4 (KUVAN, 10 mg/kg body wt)
Number of subjects: 27

Group type: EXPERIMENTAL
Intervention: Coadministration of VITC + BH4
Number of subjects: 27

Group type: COMPARATOR
Intervention: Saline (control)
Number of subjects: 27
Study: 33724103

Group type: EXPERIMENTAL
Intervention: PASTA intervention
Number of subjects: 1214

Group type: COMPARATOR
Intervention: Standard care
Number of subjects: 1214
Study: 36074201

Group type: EXPERIMENTAL
Intervention: Digital health intervention
Number of subjects: 50

Group type: COMPARATOR
Intervention: Treatment as usual
Number of subjects: 50
Study: 33517804

Group type: EXPERIMENTAL
Intervention: L-Carnitine (3000 mg daily until ovulation)
Number of subjects: 83

Group type: COMPARATOR
Intervention: Control
Number of subjects: 83

Group type: EXPERIMENTAL
Intervention: L-Carnitine
Number of subjects: 83
Study: 34818686

Group type: EXPERIMENTAL
Intervention: Mediterranean diet (MD) for 6 weeks with diet counselling
Number of subjects: 42

Group type: COMPARATOR
Intervention: Control group (CG)
Number of subjects: 42
Study: 33942065

Group type: EXPERIMENTAL
Intervention: Experimental Group B (EG B) - application of the primer and Brief Motivational Interviewing (BMI)
Number of subjects: 181

Group type: EXPERIMENTAL
Intervention: Experimental Group A (EG A) - who read the primer
Number of subjects: 181

Group type: COMPARATOR
Intervention: Control Group (CG)
Number of subjects: 181
Study: 32874108

Group type: EXPERIMENTAL
Intervention: Jump training (twice-weekly for 8 weeks)
Number of subjects: 126

Group type: COMPARATOR
Intervention: Control (regular physical education lessons)
Number of subjects: 126
Study: 36263002

Group type: EXPERIMENTAL
Intervention: Remimazolam besylate (RB) combined with alfentanil (10 μg/Kg alfentanil + RB 0.2 mg/kg intravenously)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Propofol combined with alfentanil (10 μg/Kg alfentanil + propofol 1.5 mg/kg)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Remimazolam besylate (RB) combined with alfentanil
Number of subjects: 0

Group type: COMPARATOR
Intervention: Propofol combined with alfentanil
Number of subjects: 0
Study: 34246485

Group type: EXPERIMENTAL
Intervention: Tegoprazan (200 mg) under fasting condition
Number of subjects: 24

Group type: COMPARATOR
Intervention: Tegoprazan (200 mg) under fed condition
Number of subjects: 24
Study: 34954448

Group type: EXPERIMENTAL
Intervention: Expand Your Horizon (n = 72)
Number of subjects: 135

Group type: COMPARATOR
Intervention: Active control condition (expressive writing, n = 63)
Number of subjects: 135
Study: 33229756

Group type: EXPERIMENTAL
Intervention: Recombinant EPO Beta (Recormon) administered via subcutaneous route in weekly doses of 2000 IU, 4000 IU, 6000 IU, 8000 IU, 12,000 IU, or 18,000 IU according to the severity of anemia.
Number of subjects: 40

Group type: COMPARATOR
Intervention: Not applicable (control group).
Number of subjects: 40
Study: 35089798

Group type: EXPERIMENTAL
Intervention: Second tertile of European ancestry proportion
Number of subjects: 2466

Group type: EXPERIMENTAL
Intervention: Third tertile of European ancestry proportion
Number of subjects: 2466

Group type: EXPERIMENTAL
Intervention: 5% point higher European ancestry
Number of subjects: 2466

Group type: COMPARATOR
Intervention: Intensive blood pressure treatment
Number of subjects: 2466

Group type: COMPARATOR
Intervention: Standard blood pressure treatment
Number of subjects: 2466
Study: 32660811

Group type: EXPERIMENTAL
Intervention: Therapeutic recommendation for treatment of abnormal infant heads based on perceived deformity severity.
Number of subjects: 395

Group type: EXPERIMENTAL
Intervention: Standardized photographs of children with positional cranial deformities presented to laypeople.
Number of subjects: 395

Group type: EXPERIMENTAL
Intervention: Reference values for cranial index and cranial vault asymmetry index.
Number of subjects: 395
Study: 35253334

Group type: EXPERIMENTAL
Intervention: Pioglitazone <15 mg/day
Number of subjects: 1938

Group type: EXPERIMENTAL
Intervention: Pioglitazone 15 mg/day and 30 mg/day (pooled)
Number of subjects: 1938

Group type: EXPERIMENTAL
Intervention: Pioglitazone 45 mg/day
Number of subjects: 1938

Group type: EXPERIMENTAL
Intervention: Pioglitazone 15 mg/day
Number of subjects: 1938

Group type: EXPERIMENTAL
Intervention: Pioglitazone 30 mg/day
Number of subjects: 1938

Group type: EXPERIMENTAL
Intervention: Pioglitazone <45 mg/day
Number of subjects: 1938

Group type: EXPERIMENTAL
Intervention: Pioglitazone (all doses)
Number of subjects: 1938

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1938
Study: 33964301

Group type: EXPERIMENTAL
Intervention: Subphenotype 1 (SP1) characterized by shock, acidemia, and multiorgan dysfunction.
Number of subjects: 3300

Group type: EXPERIMENTAL
Intervention: Subphenotype 2 (SP2) characterized by high C-reactive protein and early need for mechanical ventilation.
Number of subjects: 3300

Group type: EXPERIMENTAL
Intervention: Subphenotype 3 (SP3) showing the highest burden of chronic diseases.
Number of subjects: 3300

Group type: COMPARATOR
Intervention: Subphenotype 4 (SP4) demonstrating limited chronic disease burden and mild physiologic abnormalities.
Number of subjects: 3300
Study: 34085151

Group type: EXPERIMENTAL
Intervention: Tai Chi Chuan training (12 weeks)
Number of subjects: 23

Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 23
Study: 33876230

Group type: EXPERIMENTAL
Intervention: Direct-acting antiviral (DAA) treatment
Number of subjects: 113
Study: 33890515

Group type: EXPERIMENTAL
Intervention: Continuous Positive Airway Pressure (CPAP)
Number of subjects: 49

Group type: COMPARATOR
Intervention: Sham CPAP
Number of subjects: 49
Study: 33986479

Group type: EXPERIMENTAL
Intervention: NSAID pre-operative administration (Ibuprofen)
Number of subjects: 56

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 56
Study: 32812384

Group type: EXPERIMENTAL
Intervention: Fish oil group (EPA-rich fish oil: 600 mg EPA and 260 mg DHA per day for 8 weeks)
Number of subjects: 19

Group type: COMPARATOR
Intervention: Placebo group (matching capsules for the same duration)
Number of subjects: 19

Group type: EXPERIMENTAL
Intervention: Fish oil group
Number of subjects: 19

Group type: COMPARATOR
Intervention: Placebo group
Number of subjects: 19
Study: 35655285

Group type: EXPERIMENTAL
Intervention: Cornerstone intervention (lay navigator-led, early palliative care coaching)
Number of subjects: 294

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 294
Study: 34786904

Group type: EXPERIMENTAL
Intervention: Intrauterine G-CSF injections
Number of subjects: 150

Group type: EXPERIMENTAL
Intervention: Intrauterine hCG injections (500 IU)
Number of subjects: 150

Group type: COMPARATOR
Intervention: Intrauterine saline solution (placebo)
Number of subjects: 150
Study: 33350660

Group type: EXPERIMENTAL
Intervention: Standard training with a mental health awareness module
Number of subjects: 418

Group type: COMPARATOR
Intervention: Standard training
Number of subjects: 418
Study: 34169558

Group type: EXPERIMENTAL
Intervention: Dental caries
Number of subjects: 539

Group type: EXPERIMENTAL
Intervention: Periodontitis
Number of subjects: 539

Group type: EXPERIMENTAL
Intervention: Dental anxiety
Number of subjects: 539

Group type: EXPERIMENTAL
Intervention: Halitosis
Number of subjects: 539
Study: 33824113

Group type: EXPERIMENTAL
Intervention: 1% metronidazole gel
Number of subjects: 3

Group type: EXPERIMENTAL
Intervention: 1% metronidazole mouthwash
Number of subjects: 3

Group type: COMPARATOR
Intervention: Conventional treatment
Number of subjects: 3
Study: 35580701

Group type: EXPERIMENTAL
Intervention: Ketamine (target plasma concentration 100 ng/mL)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Ketamine
Number of subjects: 0
Study: 33534267

Group type: EXPERIMENTAL
Intervention: Lung-protective group (5 cmH2O positive end-expiratory pressure and recruitment manoeuvres every 30 minutes)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Lung-protective group
Number of subjects: 60

Group type: COMPARATOR
Intervention: Control group (zero end-expiratory pressure with no recruitment manoeuvres)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 60
Study: 33235184

Group type: EXPERIMENTAL
Intervention: Leflunomide (20 mg/day for 3 months)
Number of subjects: 4

Group type: EXPERIMENTAL
Intervention: Combination of leflunomide and everolimus
Number of subjects: 4
Study: 36056369

Group type: EXPERIMENTAL
Intervention: Oral diazepam before the operation
Number of subjects: 180

Group type: COMPARATOR
Intervention: Oral placebo before the operation
Number of subjects: 180
Study: 34602464

Group type: EXPERIMENTAL
Intervention: Active HD-tDCS (2mA for 20 minutes)
Number of subjects: 32

Group type: COMPARATOR
Intervention: Sham HD-tDCS
Number of subjects: 32
Study: 32816830

Group type: EXPERIMENTAL
Intervention: Fibre-fix supplement added to a low FODMAP diet
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo (control group)
Number of subjects: 0
Study: 33999741

Group type: EXPERIMENTAL
Intervention: Opioid Treatment Programs (OTP) in inpatient treatment
Number of subjects: 0

Group type: COMPARATOR
Intervention: Opioid Treatment Programs (OTP)
Number of subjects: 0
Study: 34881557

Group type: EXPERIMENTAL
Intervention: Tai Chi intervention for 12 weeks
Number of subjects: 99

Group type: COMPARATOR
Intervention: Control group (normal dietary and exercise habits)
Number of subjects: 99
Study: 35479188

Group type: EXPERIMENTAL
Intervention: Ulinastatin combined with meglumine adenosine cyclophosphate
Number of subjects: 100

Group type: COMPARATOR
Intervention: Meglumine adenosine cyclophosphate only
Number of subjects: 100
Study: 32040591

Group type: EXPERIMENTAL
Intervention: Polymyxin B (PMB)
Number of subjects: 160

Group type: COMPARATOR
Intervention: Vehicle control
Number of subjects: 160

Group type: EXPERIMENTAL
Intervention: Lipoprotein lipase (LPL) treatment
Number of subjects: 160
Study: 35998256

Group type: EXPERIMENTAL
Intervention: Heavier-load resistance training (HL; 80% 1RM)
Number of subjects: 130

Group type: EXPERIMENTAL
Intervention: Lighter-load resistance training (LL; 60% 1RM)
Number of subjects: 130

Group type: COMPARATOR
Intervention: Comparison of HL and LL
Number of subjects: 130
Study: 33478400

Group type: EXPERIMENTAL
Intervention: PerStBiRo training (N=7)
Number of subjects: 13

Group type: COMPARATOR
Intervention: Control group (N=6)
Number of subjects: 13

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 13
Study: 32014033

Group type: EXPERIMENTAL
Intervention: Novel Integrated Care Concept (NICC)
Number of subjects: 964

Group type: COMPARATOR
Intervention: Standard of Care (SoC)
Number of subjects: 964
Study: 34184544

Group type: EXPERIMENTAL
Intervention: High-resistance inspiratory muscle strength training (IMST) (30 breaths/day, 6 days/week, 75% maximal inspiratory pressure)
Number of subjects: 36

Group type: COMPARATOR
Intervention: Low-resistance sham training (15% maximal inspiratory pressure)
Number of subjects: 36
Study: 32605585

Group type: EXPERIMENTAL
Intervention: Community-based mental health care programme GBV
Number of subjects: 1000
Study: 33564887

Group type: EXPERIMENTAL
Intervention: Mindfulness-based therapeutic sailing (MBTS); three-session intervention combining nature exposure and mindfulness training.
Number of subjects: 25
Study: 33860830

Group type: EXPERIMENTAL
Intervention: Quadriceps tendon tears involving the rectus femoris (RF) or vastus lateralis/vastus medialis (VL/VM) layers
Number of subjects: 52

Group type: EXPERIMENTAL
Intervention: Presence of bony avulsion on radiographs
Number of subjects: 52

Group type: EXPERIMENTAL
Intervention: Inter-reader reliability of MRI evaluations
Number of subjects: 52

Group type: EXPERIMENTAL
Intervention: Gaps in retracted torn tendons
Number of subjects: 52
Study: 32624575

Group type: EXPERIMENTAL
Intervention: Vitamin D3 supplementation
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 0
Study: 33710353

Group type: EXPERIMENTAL
Intervention: Preoperative cleaning and disinfection of the NAC
Number of subjects: 129

Group type: COMPARATOR
Intervention: No skin treatment before surgery (Control)
Number of subjects: 129
Study: 32770686

Group type: EXPERIMENTAL
Intervention: I&D with LOOP technique
Number of subjects: 217

Group type: COMPARATOR
Intervention: I&D with packing technique
Number of subjects: 217
Study: 35460853

Group type: EXPERIMENTAL
Intervention: Ultrasound-guided SFA puncture (p-group)
Number of subjects: 107

Group type: COMPARATOR
Intervention: Traditional SFA cutdown (c-group)
Number of subjects: 107

Group type: COMPARATOR
Intervention: Comparison of time management for vascular access
Number of subjects: 107

Group type: COMPARATOR
Intervention: Type of anesthesia administered
Number of subjects: 107

Group type: COMPARATOR
Intervention: Complications
Number of subjects: 107
Study: 33196931

Group type: EXPERIMENTAL
Intervention: Wielding a gun
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (not explicitly mentioned)
Number of subjects: 0